Form 4: Aquestive Therapeutics CEO Sells Shares
Statement of Changes in Beneficial Ownership
Aquestive Therapeutics President and CEO Daniel Barber reported a sale of 8,257 shares of common stock on May 15, 2026, at a weighted average price of $4.2889 per share.
Summary
- Daniel Barber, President and CEO of Aquestive Therapeutics, Inc., sold 8,257 shares of common stock.
- The transactions occurred on May 15, 2026.
- The weighted average sale price was $4.2889 per share, with individual sale prices ranging from $4.17 to $4.64.
- Following these transactions, Mr. Barber beneficially owns 660,574 shares of common stock directly.
Sentiment
Score: 4
Explanation: StockSavvy.ai views this as a neutral to slightly negative filing due to the CEO selling shares, although the transaction was made pursuant to a Rule 10b5-1 plan, mitigating some negative sentiment.
Negatives
- Company insider, the CEO, sold a portion of his holdings.
Future Outlook
No forward-looking statements or guidance are included in this filing.
Management Comments
- The Reporting Person undertakes to provide upon request by the SEC staff, the Issuer or a security holder of the Issuer, information regarding the number of shares sold at each separate price.
Industry Context
StockSavvy.ai notes that insider selling, particularly by a CEO, can sometimes be interpreted negatively by the market, though it can also be part of pre-planned trading strategies (Rule 10b5-1 plans) or for personal financial diversification.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Rule 10b5-1 Plan | The transaction was made pursuant to a contract, instruction, or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). | Not specified, but implied to be prior to the transaction date. | Indicates a pre-planned trading strategy, which can reduce concerns about insider trading based on material non-public information. |
Stakeholder Impact
- Shareholders may view insider selling with caution, although the Rule 10b5-1 plan provides context.
- Employees may be influenced by the CEO's stock transactions as an indicator of company performance or future prospects.
Key Dates
| Date | Description |
|---|---|
| 05/15/2026 | Date of earliest transaction (sale of common stock). |
| 05/18/2026 | Date of signature on the filing. |
Keywords
Aquestive Therapeutics, AQST, Form 4, insider trading, stock sale, Daniel Barber, CEO
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.